C12N 2310/3145
With the nitrogen in 3' or 5'-position
Official title: with the nitrogen in 3' or 5'-position
C12N2310/3145 (With the nitrogen in 3' or 5'-position) appears on 95 US grants and 147 published applications in this corpus.
Search patents in C12N- Granted patents
- 95
- Published applications
- 147
- Assignees
- 43
- Inventors
- 178
- Latest grant
- 7 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 0 |
| 2003 | 0 | 5 |
| 2004 | 2 | 1 |
| 2005 | 1 | 5 |
| 2006 | 0 | 2 |
| 2007 | 0 | 8 |
| 2008 | 1 | 2 |
| 2009 | 3 | 1 |
| 2010 | 3 | 6 |
| 2011 | 7 | 2 |
| 2012 | 4 | 3 |
| 2013 | 4 | 6 |
| 2014 | 4 | 2 |
| 2015 | 4 | 9 |
| 2016 | 3 | 4 |
| 2017 | 6 | 6 |
| 2018 | 2 | 9 |
| 2019 | 5 | 9 |
| 2020 | 10 | 7 |
| 2021 | 9 | 12 |
| 2022 | 6 | 16 |
| 2023 | 7 | 11 |
| 2024 | 7 | 7 |
| 2025 | 4 | 11 |
| 2026 | 1 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Linkage modified oligomeric compounds and uses thereof7 Apr 2026US 12,595,482 B2Ionis Pharmaceuticals, Inc.
- Nucleic acid compositions and methods of multi-exon skipping16 Dec 2025US 12,497,615 B2Avidity Biosciences, Inc.
- Method of using an anti-transferrin receptor antibody to deliver an oligonucleotide to a subject having facioscapulohumeral muscular dystrophy10 Jun 2025US 12,325,753 B2Dyne Therapeutics, Inc.
- Oligonucleotides targeting frataxin and related methods27 May 2025US 12,312,585 B2University of Massachusetts
- Treatment methods for muscular dystrophy29 Apr 2025US 12,286,630 B2Sarepta Therapeutics, Inc.
- Conjugate compositions comprising phosphoryl guanidine linkages and uses thereof27 Aug 2026US 2026/0250683 A1Avidity Biosciences, Inc.
- Antisense molecules and their uses for the treatment of coronavirus infection, in particular the treatment of covid-19 related to sars-cov-2 infection13 Aug 2026US 2026/0234629 A1Ecole Nationale Veterinaire D' Alfort
- Methods for treating muscular dystrophy11 Jun 2026US 2026/0158054 A1Sarepta Therapeutics, Inc.
- Linkage Modified Oligomeric Compounds and Uses Thereof4 Dec 2025US 2025/0368995 A1Ionis Pharmaceuticals, Inc.
- Exon skipping oligomers for muscular dystrophy18 Sep 2025US 2025/0290069 A1Sarepta Therapeutics, Inc.
Most cited
By later US patents
- Antisense composition and method for treating cancer126US 7,402,574 B2AVI BioPharma, Inc. · 2008
- Splice-region antisense composition and method116US 6,784,291 B2AVI BioPharma, Inc. · 2004
- Oligonucleotide analogs having cationic intersubunit linkages114US 7,943,762 B2AVI BioPharma, Inc. · 2011
- Splice-region antisense composition and method95US 9,416,361 B2Sarepta Therapeutics, Inc. · 2016
- Splice-region antisense composition and method90US 8,895,722 B2Sarepta Therapeutics, Inc. · 2014